You've found a promising clinical trial, but it says "Phase 2." What does that mean, and should you consider enrolling? Is Phase 1 too risky? Is Phase 3 better? And why do some trials take years while others move quickly?
Understanding clinical trial phases is crucial for making informed decisions about participation. Each phase has a different purpose, different risks, and different potential benefits. Let's demystify the process from laboratory discovery to FDA approval.
Before we dive into phases, understand the journey a potential treatment takes:
Discovery (2-5 years): Scientists identify a biological target—maybe a protein that's overactive in cancer, or a pathway that's broken in Alzheimer's. They screen thousands of compounds to find one that affects that target.
Preclinical Testing (1-3 years): The promising compound is tested in cells (in vitro) and animals (in vivo). Does it work? Is it toxic? What dose seems effective? What are the side effects?
Only about 1 in 5,000 compounds that enter preclinical testing ever make it to human trials. The screening is brutal, and rightly so—we need to filter out unsafe or ineffective drugs before exposing humans to them.
Once a compound shows promise in preclinical studies, the company files an Investigational New Drug (IND) application with the FDA. If approved, human clinical trials can begin.
Primary Goal: Determine if the drug is safe enough to test further.
Secondary Goals:
Participants: 20-80 people, usually healthy volunteers OR patients with advanced disease who've exhausted standard treatments.
Duration: Several months to a year.
Success Rate: About 70% of drugs that enter Phase 1 move to Phase 2.
Phase 1 trials typically use dose escalation. The first group of participants gets a very low dose—often 1/10th of the dose that caused harm in animals. If they tolerate it well, the next group gets a higher dose. This continues until researchers find either:
For cancer drugs, Phase 1 is often therapeutic—not just safety testing. Patients with advanced cancer who've tried everything else enroll hoping the experimental drug will work. And sometimes it does. Some cancer drugs show dramatic responses even in Phase 1.
For other conditions (heart disease, diabetes, neurological disorders), Phase 1 typically uses healthy volunteers. You've seen ads: "Healthy volunteers needed, compensation $3,000." That's Phase 1.
Yes, if:
No, if:
Real story: A patient with melanoma enrolling in a Phase 1 trial of pembrolizumab (Keytruda) in 2012. The trial was testing immune checkpoint inhibition—a completely new approach. Many participants, including this patient, achieved complete remission. Pembrolizumab is now standard of care, but Phase 1 participants got it years earlier.
Primary Goal: Determine if the drug is effective for its intended use.
Secondary Goals:
Participants: 100-300 people with the condition the drug is meant to treat.
Duration: Several months to 2 years.
Success Rate: About 33% of drugs that enter Phase 2 move to Phase 3 (this is where most drugs fail).
Phase 2 is the first time researchers seriously ask: "Does this drug actually help patients?"
Early Phase 2 trials (sometimes called Phase 2a) continue dose optimization. Later Phase 2 trials (Phase 2b) look for efficacy signals—does the drug shrink tumors? Lower blood pressure? Improve symptoms?
Phase 2 trials often measure surrogate endpoints:
These aren't always the endpoints that matter most (survival, quality of life), but they can be measured faster.
Phase 2 is also where researchers identify biomarkers—genetic or molecular features that predict who will respond. A drug might fail in the overall population but show strong effects in a subgroup. This is how we've moved toward precision medicine.
Yes, if:
No, if:
Real story: A patient with cystic fibrosis enrolling in a Phase 2 trial of ivacaftor (Kalydeco) in 2009. The drug was designed for patients with a specific mutation (G551D). In Phase 2, it produced dramatic improvements in lung function—something cystic fibrosis patients rarely experience. It was fast-tracked to approval based largely on Phase 2 data because the effects were so strong.
Primary Goal: Confirm the drug works better than (or as well as) existing treatments.
Secondary Goals:
Participants: 300-3,000+ people (sometimes tens of thousands).
Duration: 1-4 years, sometimes longer.
Success Rate: About 25-30% of drugs that enter Phase 3 fail to get FDA approval.
Phase 3 is the big leagues—large, randomized, often double-blind trials comparing the new drug to current standard of care (or placebo if no effective treatment exists).
Randomization means you're assigned by chance to either:
You won't know which group you're in (double-blind means neither you nor your doctor knows). This eliminates bias and ensures scientifically valid results.
Phase 3 trials measure hard endpoints:
These trials are expensive ($100 million+ is common) and logistically complex, often running at dozens or hundreds of sites across multiple countries.
Yes, if:
Most Phase 3 trials offer excellent care. Even if you're randomized to the control arm, you get:
Note: There's a chance the experimental drug is actually worse than standard care (that's why we test it). But Phase 3 only happens when Phase 1 and 2 suggest benefit, so the odds are in your favor.
Real story: A patient with heart failure enrolling in the PARADIGM-HF trial in 2010, testing sacubitril/valsartan (Entresto). This massive Phase 3 trial (8,000+ participants) showed the drug reduced mortality by 20% compared to standard treatment. Participants in the experimental arm had measurably longer lives. Even those in the control arm got excellent care and frequent monitoring.
Primary Goal: Monitor long-term safety and effectiveness in real-world use.
Secondary Goals:
Participants: Thousands to tens of thousands of patients using the drug after FDA approval.
Duration: Ongoing, sometimes for decades.
The drug is already FDA-approved and available by prescription. Phase 4 studies are observational or interventional, tracking:
Sometimes Phase 4 studies lead to label expansions (approval for new conditions) or restrictions (warnings about specific side effects).
Phase 4 trials are low-risk—you're taking an FDA-approved drug anyway. Participation usually just means allowing your data to be collected and perhaps completing surveys about your experience.
Benefits: Contributing to medical knowledge, often with modest compensation, and sometimes closer monitoring than you'd get otherwise.
Real story: Patients taking Lipitor (atorvastatin) participating in Phase 4 studies that eventually showed the drug also reduced stroke risk, leading to expanded indications.
Traditional phase structure is evolving. Some modern trials blur the lines:
Adaptive trials: Modify in real-time based on accumulating data. If one dose clearly works better, more patients are assigned to that dose. If a biomarker predicts response, enrollment focuses on biomarker-positive patients.
Basket trials: Test one drug across multiple cancer types united by a shared genetic mutation (e.g., NTRK fusions). These can span Phase 1-3 simultaneously in different tumor types.
Umbrella trials: Test multiple drugs for one disease (e.g., lung cancer), assigning patients based on their tumor's specific mutations.
Seamless Phase 1/2 or 2/3 trials: Combine phases to accelerate development.
These designs are more efficient but can be confusing. "What phase am I in?" becomes less clear. Focus instead on the trial's goals and whether they match your situation.
Ask these questions:
What is this trial trying to learn? Safety? Efficacy? Comparison to standard care?
What's required of me? How many visits? What tests? Any procedures?
What are the risks? Based on the phase, what's known and unknown about safety?
What are the potential benefits? Realistic assessment, not hype.
Who's running it? Reputable institution? Experienced investigators?
Who's sponsoring it? Pharmaceutical company? NIH? Academic center?
What happens when the trial ends? Do I keep getting the drug? What's the transition plan?
Of the small percentage of compounds that make it to Phase 1:
This isn't failure—it's science working. We're filtering out drugs that don't work well enough or have unacceptable side effects. Every "failed" trial teaches us something.
But for participants, it can be disappointing. You might enroll in a Phase 2 trial hoping for the next breakthrough, only to learn the drug doesn't work.
That's why informed consent is critical. Understand that experimental means uncertain.
Clinical trials aren't just a last resort. They're where cutting-edge medicine happens, where you can access treatments years before they're widely available.
But they're not for everyone or every situation. Consider:
Talk to your doctor. Get a second opinion. Research the investigator and institution. Read the consent form carefully (it's long, but read it).
And remember: participating in a trial, regardless of phase, contributes to medical progress. Future patients will benefit from what you help discover.
Search clinical trials by phase at crick.ai/trials
Discover more articles about precision medicine and biomedical research.
View All Posts